<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959231</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000643641</org_study_id>
    <secondary_id>CRUK-UCL-RIC-UCBT</secondary_id>
    <secondary_id>EUDRACT-2004-003845-41</secondary_id>
    <secondary_id>EU-20946</secondary_id>
    <nct_id>NCT00959231</nct_id>
  </id_info>
  <brief_title>Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease</brief_title>
  <official_title>Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Haematological Diseases Using a Reduced Intensity Conditioning Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor&#xD;
      umbilical cord blood transplant helps stop the growth of abnormal cells. It also stops the&#xD;
      patient's immune system from rejecting the donor's stem cells. The donated stem cells may&#xD;
      replace the patient's immune cells and help destroy any remaining abnormal cells&#xD;
      (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an&#xD;
      immune response against the body's normal cells. Giving cyclosporine and mycophenolate&#xD;
      mofetil before and after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of donor umbilical cord blood&#xD;
      transplant after cyclophosphamide, fludarabine phosphate, and total-body irradiation in&#xD;
      treating patients with hematologic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To assess the safety and efficacy of unrelated-donor umbilical cord blood&#xD;
           transplantation (UCBT) using a nonmyeloablative preparative regimen in patients with&#xD;
           hematological disease, in a multi-institution UK setting.&#xD;
&#xD;
        -  To confirm that unrelated-donor UCBT following nonmyeloablative conditioning is&#xD;
           associated with consistent and durable engraftment in these patients.&#xD;
&#xD;
        -  To assess transplant-related mortality at day 100 associated with nonmyeloablative UCBT&#xD;
           in these patients.&#xD;
&#xD;
        -  To assess the incidence of grades II-IV and III-IV acute graft-vs-host disease (GVHD) in&#xD;
           these patients.&#xD;
&#xD;
        -  To assess the risk of relapse and progressive disease in these patients at 1 year post&#xD;
           transplant after nonmyeloablative UCBT.&#xD;
&#xD;
        -  To assess overall and progression-free survival of these patients at 1 year after&#xD;
           nonmyeloablative UCBT.&#xD;
&#xD;
        -  To assess immune reconstitution at 1, 2, 3, 6, 12, and 24 months after transplant as&#xD;
           measured by quantitative recovery of B, T, and NK cells (flow cytometry), qualitative&#xD;
           recovery of T cells (TREC and spectratyping), in vivo functional T-cell responses (EBV&#xD;
           and CMV tetramers), and quantitative immunoglobulins.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Reduced-intensity conditioning regimen: Patients receive cyclophosphamide IV over 2&#xD;
           hours on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -2. Patients&#xD;
           undergo a single fraction of total-body irradiation on day -1.&#xD;
&#xD;
        -  Umbilical cord blood (UCB) transplantation: Patients undergo umbilical cord blood&#xD;
           transplantation on day 0.&#xD;
&#xD;
        -  Graft-vs-host disease prophylaxis: Patients receive cyclosporine IV or orally on days -3&#xD;
           to 100 followed by taper and mycophenolate mofetil IV or orally on days -3 to 35&#xD;
           followed by taper.&#xD;
&#xD;
      Blood and bone marrow samples are collected periodically for analysis.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months in year 1, every&#xD;
      4 months in year 2, every 6 months until 5 years, and then annually thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-relapse mortality at day 100</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades II-IV and III-IV acute graft-vs-host disease (GVHD) at day 100 and chronic GVHD at 1 year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mixed chimerism</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemopoietic recovery</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hematopoietic/Lymphoid Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of high-risk, advanced or poorly responding hematological disease for which&#xD;
             a reduced-intensity hemopoietic stem cell transplantation is likely to be effective&#xD;
&#xD;
               -  Disease status is such that there is no alternative therapy likely to achieve a&#xD;
                  cure or provide a significant prolongation of disease-free survival&#xD;
&#xD;
          -  No chronic myelogenous leukemia in first chronic phase responding to imatinib or&#xD;
             refractory blast crisis&#xD;
&#xD;
          -  No acute leukemia in morphological relapse/persistent disease (defined as &gt; 5% blasts&#xD;
             in normocellular bone marrow)&#xD;
&#xD;
          -  No malignant disease that is refractory to or progressive on salvage therapy&#xD;
&#xD;
          -  No myelofibrosis&#xD;
&#xD;
          -  Donor must be matched at HLA-A and -B at antigen level and HLA-DRB1 at allelic level&#xD;
&#xD;
               -  No available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor OR 10/10 unrelated&#xD;
                  volunteer donor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 60-100% OR Lansky PS 50-100% (pediatrics)&#xD;
&#xD;
          -  Transaminases &lt; 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 3 times ULN&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  DLCO &gt; 50% predicted&#xD;
&#xD;
          -  No supplemental oxygen requirements&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No HIV or HTLV (I and II) antibody positivity or evidence of infection&#xD;
&#xD;
          -  No acquired aplastic anemia&#xD;
&#xD;
          -  No decompensated congestive heart failure or uncontrolled arrhythmia and left&#xD;
             ventricular ejection fraction â‰¥ 35%&#xD;
&#xD;
          -  No current active serious infection, in particular uncontrolled fungal infection&#xD;
&#xD;
          -  No congenital immune deficiencies&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 6 months since prior exposure to combination chemotherapy OR only 1 course&#xD;
             of induction combination chemotherapy for myelodysplastic syndromes or acute myeloid&#xD;
             leukemia (please discuss with study coordinator/s if this course contained&#xD;
             fludarabine)&#xD;
&#xD;
          -  At least 6 months since prior myeloablative bone marrow transplantation&#xD;
&#xD;
          -  No prior irradiation that precludes the safe administration of an additional dose of&#xD;
             200 cGy of total-body irradiation&#xD;
&#xD;
          -  No prior autograft&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachael Hough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-117-342-8044</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Clinical Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-206-6020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2PQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Hough, MD</last_name>
      <phone>44-845-155-5000 ext. 5239</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1E 6DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-207-830-2301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-207-813-8335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Newcastle-Upon-Tyne Northern Institute for Cancer Research</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-191-222-7785</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>hematopoietic/lymphoid cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

